DRUG
Fiscal year ends September Quarters are offset from the calendar — Q1 is Oct–Dec

Bright Minds Biosciences Inc. is a biotechnology company developing therapeutics for neurological and psychiatric disorders. The company focuses on a platform of highly selective serotonergic agonists, specifically targeting 5-HT2A and 5-HT2C receptor subtypes, to address conditions with high unmet medical need. Its lead program, BMB-101, is a 5-HT2C selective agonist designed as an anti-epileptic drug for hard-to-treat patient populations, including Dravet Syndrome and generalized seizures. BMB-101 has completed Phase 1 clinical studies and initiated Phase 2 trials in 2024. The company also maintains a portfolio of new chemical entity programs, including BMB-201 and BMB-202, which are selective 5-HT2A agonists for neuropsychiatry and neurology indications currently undergoing IND-enabling studies. Bright Minds Biosciences Inc. operates through two wholly-owned subsidiaries: Bright Minds Biosciences LLC and Bright Minds Bioscience Pty. Ltd. The company was incorporated in 2019 under the name 1210954 B.C. Ltd. and changed its name to Bright Minds Biosciences Inc. in 2020.

Summarised from the company's own disclosures, fiscal year ended Dec 2024

Industry Biotechnology Homepage brightmindsbio.com
Sector Healthcare IR page investors.brightmindsbio.com
Tags
neurology, psychiatry, epilepsy, serotonergic agonists, 5-ht2c agonists, 5-ht2a agonists, central nervous system disorders, drug-resistant epilepsy, dravet syndrome, depression, BMB-101, BMB-201, BMB-202, Bright Minds Biosciences LLC, Bright Minds Bioscience Pty. Ltd.
Press page —

Metrics

Valuation  
Market cap $ 342.665M
Market cap (USD) $ 342.665M
P/E -39.70
PEG —
P/BV 5.92
P/S —
P/OCF -55.92
P/FCF -55.92
Dividend yield —
Turnover / mcap —
Returns  
ROE -27.9%
ROI —
ROIC —
Profit margin —
Growth  
Revenue growing —
Profits growing No
Revenue up 3y —
Revenue up 5y —
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding —
Buying back stock No
Diluting (TTM) Yes
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 22
Quality score -80.0%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021
Assets 84.422M 6.105M 6.879M 12.087M 20.04M
Net profit -12.229M -2.802M -7.372M -14.965M -8.651M
Free cash flow -8.692M -1.85M -7.024M -13.587M -7.319M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021
Share price 84 1.6 2.14 1.58 15.85
Price performance 12m 50.85 -0.26 0.29 — —

Filed figures

Figure Sep 2020 Sep 2021 Sep 2022 Sep 2023 Sep 2024 Sep 2025
Income detail
Research and development expense (CAD) 354,852 6.31M 12.2M 5M 1.18M 11.1M
↳ 5y CAGR +99.0%
Reported Dec 29, 2022 Dec 29, 2022 Dec 29, 2022 Dec 29, 2023 Dec 31, 2024 Dec 23, 2025

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

November 2, 2026

PDF Version

NEW YORK, Nov. 02, 2026 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE: DRUG) (NASDAQ: DRUG) (“Bright Minds” or the “Company”) announces that the U.S. Food and Drug Administration (“FDA”) has notified the Company via email that its investigational new drug application (“IND”) for Developmental and Epileptic Encephalopathies (“DEEs”) and related Protocol BMB-101-105 has been placed on a partial clinical hold following the FDA’s review.

The proposed trial related to this IND is a randomized, placebo-controlled, double-blind Phase 2 study designed to evaluate the efficacy and safety of ascending doses of BMB-101, up to a maximum tolerated dose, for the treatment of seizures associated with DEEs.

The Company believes that the partial clinical hold covers only the planned Phase 2 trial of BMB-101 in DEE in the United States, and the partial clinical hold does not affect the Company’s other ongoing clinical trials.

The primary reason given by the FDA relates to identified toxicity in mice, and inadequate pharmacokinetic and juvenile toxicity data to support the proposed pediatric enrollment.

The Company believes that the FDA’s observation of toxicity in mice was not seen in any other species. The Company further believes, based on its toxicity reports, peer reviewers, and multiple independent toxicology expert opinions, that the adverse mouse findings were incidental and not drug-related. These are the Company’s beliefs and should not be understood as the FDA findings or as resolving the FDA’s stated concerns.

The Company is awaiting the FDA’s full Partial Clinical Hold Letter. The FDA stated that it would provide the letter within 30 days, including additional details, non-hold recommendations, and study-design recommendations.

Bright Minds intends to immediately request further clarification from the FDA. The Company plans to review the FDA’s Partial Clinical Hold Letter and refine the study in accordance with the FDA’s recommendations with the objective of addressing the identified issues and advancing future U.S. clinical trials. Additional data or studies may be required, and there can be no assurance as to when or whether the partial clinical hold will be lifted or future U.S. trials will be permitted to proceed.

About BMB-101

BMB has completed two clinical trials with BMB-101. To date approximately 90 subjects have received BMB-101 across all the Company’s clinical programs.

Phase 1: In a placebo-controlled single-ascending-dose, multiple-ascending-dose and food-effect studies conducted in 64 healthy volunteers, BMB-101 was well tolerated at all doses tested. There were no serious adverse events, and adverse events were mild and consistent with on-target serotonergic effects. There were no drug-related serious adverse events.

On January 6, 2026, the Company announced the topline data from its Phase 2 BREAKTHROUGH trial. In 24 adults with drug-resistant absence seizures or DEE, most of whom were taking three to five other anti-seizure medications, 79.6% of treatment-emergent adverse events were mild and 17.2% were moderate. No drug-related serious adverse events occurred. Six DEE patients completed the main study treatment with median reduction of motor seizures of 63.3%. All five DEE patients who entered the open label extension remain on therapy with BMB-101.

About Bright Minds

Bright Minds is a biotechnology company developing innovative treatments for patients with neurological and psychiatric disorders. Our pipeline includes novel compounds targeting key receptors in the brain to address conditions with high unmet medical need, including epilepsy, depression, and other CNS disorders. Bright Minds is focused on delivering breakthrough therapies that can transform patients' lives.

Bright Minds has developed a unique platform of highly selective serotonergic agonists exhibiting selectivity at different serotonergic receptors. This has provided a rich portfolio of NCE programs within neurology and psychiatry.

REPORT OF VOTING RESULTS Bull 0 Bear 0 Routine

Pursuant to Section 11.3 of National Instrument 51-102 - Continuous Disclosure Obligations, the following is the report on voting results for the annual general meeting of shareholders of Bright Minds Biosciences Inc. ("the Company") held on March 31, 2026 (the "Meeting").

The Company reports that a total of 7,877,637 common shares were voted at the Meeting, representing 80.49% of the votes attached to the common shares outstanding as of the record date for the Meeting. Voting results on the resolutions were as follows:

1. Election of Directors

The six nominees for election to the Board of Directors received votes as follows.

Nominee Votes For % Votes For Votes Withheld % Votes Withheld

Ian McDonald 7,564,151 99.99% 492 0.01%

Nils Bottler 6,789,827 89.76% 774,816 10.24%

Jeremy Fryzuk 7,384,419 97.62% 180,224 2.38%

Jan Pedersen 6,995,861 92.48% 568,782 7.52%

David Weiner 7,384,084 97.61% 180,559 2.39%

2. Appointment of Auditors

De Visser Gray LLP, Chartered Professional Accountants, were appointed as the auditor of the Company. Shares voted in person and by proxy represented 7,872,821 votes FOR, being 99.94% and 4,816 votes WITHHELD, being 0.06%.

September 30, 2026

PDF Version

NEW YORK, Sept. 30, 2026 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE: DRUG) (NASDAQ: DRUG) (“Bright Minds” or the “Company”), a clinical stage biotechnology company focused on developing highly selective 5-HT2 agonists for the treatment of drug-resistant epilepsy, Prader-Willi Syndrome, depression, and other central nervous system (CNS) disorders, today announced that it will participate in the Foundation for Prader-Willi Research (FPWR) 2026 Research Symposium, October 7-8, and the PWS Family Conference, October 9-10, at the Marriott Philadelphia Downtown.

The FPWR meeting brings together families, caregivers, clinicians, researchers, and industry to share the latest in PWS research and care. Bright Minds' participation reflects the Company's commitment to developing a therapy that addresses both hyperphagia and the neurobehavioral symptoms of PWS, and to keeping the PWS community closely involved as its clinical program advances.

"There is no therapy today that adequately addresses the full burden of Prader-Willi Syndrome: the relentless hunger and the behavioral and psychiatric challenges that families live with every day," said Ian McDonald, Chief Executive Officer and Co-founder of Bright Minds Biosciences. "The FPWR community has shaped how we think about this disease, from the outcome measures we use to the way we design our studies. We are proud to support this year's meeting and to spend time with the families and researchers who are driving progress in PWS. Our NOVA study of BMB-101 is under way. We believe selective 5-HT2C agonism has the potential to address the underlying biology of PWS rather than a single symptom."

Bright Minds' PWS Program

Individuals with PWS have reduced levels of functional 5-HT2C receptors, which are central regulators of appetite, satiety, and behavior. Bright Minds is developing highly selective, Gq-biased 5-HT2C agonists designed to restore signaling through this pathway while avoiding the receptor desensitization and 5-HT2B-related cardiac liabilities that limited earlier serotonergic agents.

BMB-101 is being evaluated in NOVA, a randomized, double-blind, placebo-controlled Phase 2a study assessing the effect of BMB-101 on hyperphagia (primary endpoint: change from baseline in the Hyperphagia Questionnaire for Clinical Trials, HQ-CT), PWS-associated behaviors, and safety and tolerability over a 16-week treatment period, with an optional open-label extension.

In November 2025, the Company expanded its Scientific Advisory Board with four global PWS experts, including Theresa V. Strong, PhD, a founding member of FPWR and its Director of Research Programs; Jennifer L. Miller, MD, University of Florida; Elizabeth Roof, H.S.P., M.A., Vanderbilt University; and Tania Markovic, MBBS PhD FRACP, Royal Prince Alfred Hospital, Sydney.

About Prader-Willi Syndrome

Prader-Willi syndrome (PWS) is a rare genetic neurodevelopmental disorder resulting from abnormal gene expression on chromosome 15, affecting approximately one in every 15,000 live births. The hallmark feature of PWS is hyperphagia, a chronic, life-threatening condition marked by an unrelenting feeling of hunger, obsessive thoughts about food, and a lack of normal satiety. Hyperphagia is associated with serious health risks, including choking, stomach rupture, and accidental death related to food-seeking, as well as obesity, type 2 diabetes, and cardiovascular disease. Individuals with PWS also experience significant neurobehavioral challenges, including emotional dysregulation, compulsivity, temper outbursts, and cognitive impairment. Currently available therapies address hyperphagia only; there are no approved treatments for the neurobehavioral symptoms of PWS.

Corporate Update

The Company also announces that it has entered into a mutual rescission and release agreement with an officer of the Company rescinding the officer's prior exercise of stock options in respect of 44,500 common shares. The 44,500 shares issued on that exercise will be returned to treasury and cancelled, the aggregate exercise price will be refunded to the officer, and the options are restored on their original terms, including exercise price, vesting schedule and expiry date, under the Company's share option plan. No other options are affected.

About Bright Minds Biosciences

Bright Minds is a biotechnology company developing innovative treatments for patients with neurological and psychiatric disorders. Our pipeline includes novel compounds targeting key receptors in the brain to address conditions with high unmet medical need, including epilepsy, Prader-Willi Syndrome, depression, and other CNS disorders. Bright Minds is focused on delivering breakthrough therapies that can transform patients' lives.

Bright Minds has developed a unique platform of highly selective serotonergic agonists exhibiting selectivity at different serotonergic receptors. This has provided a rich portfolio of NCE programs within neurology and psychiatry.

Prompts

Bright Minds Biosciences Inc. (ticker DRUG), listed in United States.

ETFs Holding Bright Minds Biosciences Inc.

ETF Weight in ETF Shares Market value As of
PSIL 2.60% 48,217 $ 988.931K Nov 17, 2026
FSEG 0.06% 48 $ 3,369.60 Jun 30, 2026
RESM 0.02% 9 $ 631.80 Jun 30, 2026
FESM 0.01% 7,054 $ 495.191K Jun 30, 2026
AVSC 0.00% 6,249 $ 141.29K Nov 16, 2026